Compare BridgeBio Pharma Inc (BBIO) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $122.36. The key difference: Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | QQQE | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $122.72 |
52-Week Low | $47.29 | $96.06 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQE trades at $121.96, up 1.61% with strong bullish technical signals from moving averages. The equal-weighted Nasdaq-100 ETF offers diversified exposure to large-cap growth stocks, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights SpaceX's potential Nasdaq-100 inclusion as a catalyst for equal-weighted strategies.
The ETF's equal-weight approach provides defensive positioning amid tech concentration concerns, with recent outperformance driven by mid-tier growth and biotech exposure. Key risks include market volatility and tech sector sensitivity, while institutional interest grows due to balanced Nasdaq exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
